Safety, Tolerability, and Preliminary Efficacy of KD01 Via Intravesical Instillation in Bladder Cancer (BC)

NCT07359235 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer (BC)

Interventions

DRUG: KD01(the recombinant oncolytic adenovirus)

Sponsor

Tongji Hospital